Rick Ascroft, head of the U.S. Plasma-Derived Therapies Business Unit, sheds light on the reality of patients living with chronic inflammatory demyelinating polyneuropathy (#CIDP), discusses Takeda’s rich history in plasma and shares insights into better supporting people living with CIDP. Read more about CIDP and the work we do to support patients with this illness. https://lnkd.in/ehkeQwiC
Takeda’s Post
More Relevant Posts
-
Director, Global Clinical Supply Chain | Director, MCPHS/Takeda PharmD Fellowship in Global Clinical Supply Chain
An illuminating read from Rick Ascroft, head of U.S. Plasma-Derived Therapies Business Unit, about #CIDP management and the opportunity we have through our work each day to improve patient outcomes. So important to elevate awareness of this and other #RareDiseases. #TeamTakeda
Rick Ascroft, head of the U.S. Plasma-Derived Therapies Business Unit, sheds light on the reality of patients living with chronic inflammatory demyelinating polyneuropathy (#CIDP), discusses Takeda’s rich history in plasma and shares insights into better supporting people living with CIDP. Read more about CIDP and the work we do to support patients with this illness. https://lnkd.in/ehkeQwiC
Unlocking the Potential in CIDP: A Call to Innovation, Collaboration and Follow-through
Richard Ascroft on LinkedIn
To view or add a comment, sign in
-
How do Physicians consider and ultimately prescribe a therapy for a patient diagnosed with Multiple Sclerosis? There are many market research/syndicated studies that aid in understanding the performance of a particular therapy in a disease area - RxY stands out as the only syndicated study to support the true why / why not - behind physician treatment choices for dynamic patients. At RxY, we purposefully design our patient chart audit in order to bridge the qualitative-quantitative gap and address this question. The RxY Multiple Sclerosis patient chart audit includes: • Focusing on Dynamic Patients - initiations and switches. Understanding the true why/why not for-why a physician considers and prescribes a therapy. This allows our clients to win greater patient shares, by making data driven decisions that optimize marketing strategies. • Collection and analysis of the following number of Dynamic Patient charts within the Multiple Sclerosis therapeutic area: o USA - 7,937 since 2020 o EU5 - 5,944 since 2021 o Japan - 715 in 2023 o Brazil - 270 in 2023 • Treatment decision verbatims collected from physicians on the true why / why not o USA - 39,685 o EU - 29,720 o Japan - 3,575 o Brazil - 1,350 • Delivery of rich qualitative data with the confidence of robust quantitative samples If you would like to learn more about our work at RxY and see the complete list of Therapy Areas we cover, visit our website - https://lnkd.in/dsP-cHqU Please feel free to contact me directly if you have any questions [email protected]
RxY
rxyhc.com
To view or add a comment, sign in
-
🧠 𝐁𝐥𝐨𝐨𝐝 𝐓𝐞𝐬𝐭 𝐂𝐨𝐮𝐥𝐝 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐞 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫'𝐬 𝐅𝐢𝐠𝐡𝐭 🧠 📌𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅𝐬 𝐚𝐭 𝐘𝐨𝐮𝐫 𝐅𝐢𝐧𝐠𝐞𝐫𝐭𝐢𝐩𝐬: https://lnkd.in/eFncdXW9 (𝙐𝙨𝙚 𝘾𝙤𝙧𝙥𝙤𝙧𝙖𝙩𝙚 𝙈𝙖𝙞𝙡 𝙄𝙙 𝙛𝙤𝙧 𝙌𝙪𝙞𝙘𝙠 𝙍𝙚𝙨𝙥𝙤𝙣𝙨𝙚) 𝑰𝒎𝒂𝒈𝒊𝒏𝒆 𝒂 𝒔𝒊𝒎𝒑𝒍𝒆𝒓 𝒘𝒂𝒚 𝒕𝒐 𝒅𝒆𝒕𝒆𝒄𝒕 𝑨𝒍𝒛𝒉𝒆𝒊𝒎𝒆𝒓'𝒔 𝒅𝒊𝒔𝒆𝒂𝒔𝒆, 𝒚𝒆𝒂𝒓𝒔 𝒃𝒆𝒇𝒐𝒓𝒆 𝒔𝒚𝒎𝒑𝒕𝒐𝒎𝒔 𝒂𝒑𝒑𝒆𝒂𝒓! A groundbreaking blood test is on the horizon, offering a less invasive and potentially more accessible method for early diagnosis. This is a game-changer for millions affected by Alzheimer's. 📌𝑾𝒉𝒚 𝒊𝒔 𝒆𝒂𝒓𝒍𝒚 𝒅𝒆𝒕𝒆𝒄𝒕𝒊𝒐𝒏 𝒔𝒐 𝒊𝒎𝒑𝒐𝒓𝒕𝒂𝒏𝒕? 𝑬𝒂𝒓𝒍𝒊𝒆𝒓 𝒊𝒏𝒕𝒆𝒓𝒗𝒆𝒏𝒕𝒊𝒐𝒏: Treatments are more effective when started sooner! This blood test could give patients a head start in managing the disease. 𝑰𝒎𝒑𝒓𝒐𝒗𝒆𝒅 𝒑𝒍𝒂𝒏𝒏𝒊𝒏𝒈: Early diagnosis allows families to make informed care decisions. 𝑹𝒆𝒅𝒖𝒄𝒆𝒅 𝒉𝒆𝒂𝒍𝒕𝒉𝒄𝒂𝒓𝒆 𝒄𝒐𝒔𝒕𝒔: This test could eliminate the need for expensive procedures. 𝑭𝒂𝒔𝒕𝒆𝒓 𝒄𝒍𝒊𝒏𝒊𝒄𝒂𝒍 𝒕𝒓𝒊𝒂𝒍𝒔: It provides a simpler way to identify and monitor participants in Alzheimer's research. This is a huge step forward in the fight against Alzheimer's! It offers hope for better patient outcomes, improved quality of life, and further advancements in treatment and care. 🔵 𝑲𝒆𝒚 𝑪𝒐𝒎𝒑𝒂𝒏𝒊𝒆𝒔 𝑷𝒓𝒐𝒇𝒊𝒍𝒆𝒅 AbbVie Teva Pharmaceuticals Eisai US Janssen Pharmaceuticals, Inc. Novartis Zydus Group Sun Pharmaceutical Sdn Bhd Dr. Reddy's Laboratories AUROBINDO PHARMA LTD #Alzheimers #EarlyDetection #BloodTest #Hope #Breakthrough #Healthcare #Caregivers #Family #Research #FutureofMedicine #Alzheimer #future #innovation #health #medicine Disclaimer- I don't intend any copyright (DM me for credit & removal)
To view or add a comment, sign in
-
The risk of over diagnosis is too great already. This would only make it worse. "...In a response, the American Geriatrics Society has said that expanding the definition of Alzheimer’s in such a way could risk overdiagnosis, which 'could lead to initiation of treatments with limited benefit and high potential for harm.' "Older adults with a dementia diagnosis might additionally face discrimination from employers or insurers..." (Source: https://lnkd.in/geqXW__h) A warning was issued in 2012: "...the cumulative burden from overdiagnosis poses a significant threat to human health..." (See reference to complete study in comment.) #prevention #overdiagnosis #dementia #alzheimers #geriatrics #gerontology #employers #insurers #healthcare
Helping the aging services industry in igniting change through training, education and resident engagement programs anchored in quality of life.
On one hand, support for earlier diagnosis can expand access to resources - particularly education on diet and lifestyle changes that can help with disease progression. On the other hand, this call out in the article is NOT ok! "The organization also criticized what it saw as “wholly inappropriate” conflicts of interest within the working group that proposed the change, which had ties to the pharmaceutical industry." Making decisions that prioritize financial gain vs. the true health of individuals has to stop. Modern medicine has done wonders, but pushing drugs is not the answer to overall health and well-being. What are your thoughts?
New Definition of Alzheimer’s Would Expand Diagnosis to People Without Memory Problems
https://seniorhousingnews.com
To view or add a comment, sign in
-
AccendoWave - A Pain #Data Company Investigators concluded that global assessment measures in chronic #pain trials need further improvement. A Top 4 Global Health Equity Solution and Top 15 Global Remote Monitoring Company, AccendoWave, benchmarks objective brain wave pain data (specialty, gender, age) and has nine #pain databases: Emergency Department, Maternal Health, Oncology, MSK, Medical Surgical, ICU, hashtag #Women, Adults, Seniors to eliminate bias, improve outcomes and reduce health care costs. If desired, AccendoWave can also create customized pain databases for partners that can be accessed on the Datavant platform.
Analyzing Patient-Reported Assessments for Global Measures in Treatments for Chronic Pain
https://www.physiciansweekly.com
To view or add a comment, sign in
-
We need better access to non-pharmacologic treatments. Payers need to step up coverage for what we now know is best practice for pain. Non-pharmacologic care is most comprehensively provided by Chiropractors and Physical Therapists. #spinecarepartners #physical therapy
Chronic Pain in the US: New Data
medscape.com
To view or add a comment, sign in
-
#Mentalhealth care is fraught with treatment-resistant conditions and ineffective or side-effect-ridden therapies, but - as Angela T. discusses - #psychedelictherapy holds immense promise for addressing the limitations of existing #treatments. https://lnkd.in/gaxnwXUx
What the FDA’s groundbreaking guidance really means for psychedelic therapy clinical trials
pharmaphorum.com
To view or add a comment, sign in
-
knownwell, an in-person and virtual, weight-inclusive primary care and metabolic health company, announced a funding raise of $20M, led by industry veterans at Andreesen Horowitz, or a16z Bio + Health. The company is headed by Brooke Boyarsky Pratt who has had lifelong obesity, and Dr. Angela Fitch MD, FACP, FOMA, Dipl. ABOM, President of the Obesity Medicine Association. The approach is to offer weight-inclusive care, in a shame and blame-free care model, within primary care clinics and on a technology platform, incorporating ‘…AI-powered patient stratification, asynchronous communication, and provider workflow enablement tools.’ With over 40% of the U.S adult population and almost 20% of children and adolescents suffering from obesity in the U.S., I am all for compassionate, whole-person care; but how will knownwell measure and drive better clinical outcomes? Despite this, I wholeheartedly welcome investment in the obesity and medical care start-up space, for us to assume deliberate focus on accessible, highest quality, cost permissive care, to the 110 million Americans that need it, and counting! https://lnkd.in/epy4HbEA
knownwell Raises $20M Series A From A16Z to Scale the First Patient-Centered Healthcare Home For Those With Overweight and Obesity
businesswire.com
To view or add a comment, sign in
-
Fludarabine had a significant shortage in 2022. Patients on CAR-T therapy require fludarabine-based lymphodepleting regimens prior to CAR-T therapy, but due to the shortage, CAR-T centers had to switch some patients to cyclophosphamide-based or bendamustine-based regimens. This abstract looked at the various lymphodepleting regimens used before BCMA-directed CAR-T therapy from 13 academic institutions. It found that, when adjusting for other prognostic factors, there did not appear to be a difference in PFS between fludarabine-based regimens and non-fludarabine based regimens. It's good to know that this shortage did not appear to have any impact on patient outcomes in multiple myeloma. #ash2023 https://lnkd.in/e5_SPGd8
To view or add a comment, sign in
-
Helping the aging services industry in igniting change through training, education and resident engagement programs anchored in quality of life.
On one hand, support for earlier diagnosis can expand access to resources - particularly education on diet and lifestyle changes that can help with disease progression. On the other hand, this call out in the article is NOT ok! "The organization also criticized what it saw as “wholly inappropriate” conflicts of interest within the working group that proposed the change, which had ties to the pharmaceutical industry." Making decisions that prioritize financial gain vs. the true health of individuals has to stop. Modern medicine has done wonders, but pushing drugs is not the answer to overall health and well-being. What are your thoughts?
New Definition of Alzheimer’s Would Expand Diagnosis to People Without Memory Problems
https://seniorhousingnews.com
To view or add a comment, sign in